[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N)

Upstate Institutional Review Board (IRB) Number:

1476715

Study/Protocol ID:

CACZ885V2201C

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

What is involved if I participate?

  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No

ClinicalTrials.Gov ID:

NCT03968419

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Eunice B Awuah, PhD
Phone: 315-464-5934
Email: awuahe@upstate.edu

Return to Previous Page || Search Again

Top